To hear about similar clinical trials, please enter your email below
Trial Title:
Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study
NCT ID:
NCT06150222
Condition:
Cancer, Cervical
Recurrence
Metastasis
Conditions: Official terms:
Neoplasm Metastasis
Recurrence
Conditions: Keywords:
Reirradiation
OligoRecurrence
Oligometastasis
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Other
Intervention name:
Concurrent Chemoradiation, Systemic Chemotherapy other locally directed therapies (like surgery, ablation, etc.)
Description:
The aim is to include all patients with (induced) oligo metastatic and oligo recurrent
settings, irrespective of whether treated with concurrent chemoradiation, systemic
chemotherapy, or with other locally directed therapies (like surgery, ablation, etc.)
Summary:
This multi centric international retrospective study aims to register patients with oligo
metastatic and oligo recurrent cervical cancer. The study will register patients in
planned period with an aim to analyse clinical outcomes with or without use of radiation
in this setting.
Detailed description:
Detailed clinical protocol can be obtained by contacting the principal investigator.
Criteria for eligibility:
Study pop:
All patients with (induced) oligo metastatic and oligo recurrent settings irrespective of
whether radiation was used or not.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. Cervical cancer with (induced) oligo-metastatic and/or oligo-recurrent cervix cancer
whether treated or not treated with radiation. These patients may have received
previous treatment within or outside approved clinical trials/studies.
2. Patients with poly-metastatic disease with good response to systemic chemotherapy
and treated with radiation to recurrence or metastatic site.
3. Patients treated with radical doses at the time of first diagnosis of
oligo-metastasis/oligo-recurrence and present with further oligo-progression.
4. Patients with oligo-metastasis or oligo-recurrence treated with other locally
directed therapies (like surgery, ablation, etc.) are also permitted.
Exclusion Criteria:
1. Gynecological cancer other than cervical cancer
2. Persistent Poly-metastatic disease post systemic treatment
3. Receiving investigational new drugs at the time of relapse as part of other ongoing
trials
4. No clinical follow up after treatment
Gender:
Female
Minimum age:
18 Years
Maximum age:
100 Years
Healthy volunteers:
No
Start date:
November 30, 2023
Completion date:
July 31, 2027
Lead sponsor:
Agency:
Erasmus Medical Center
Agency class:
Other
Collaborator:
Agency:
Tata Memorial Centre
Agency class:
Other
Source:
Erasmus Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06150222
